BerGenBio Logo

BerGenBio

Develops first-in-class AXL kinase inhibitors for cancer and severe respiratory infections.

BGBIO | OL

Overview

Corporate Details

ISIN(s):
NO0012921180 (+2 more)
LEI:
213800TYYFXKYF3V2A23
Country:
Norway
Address:
MØLLENDALSBAKKEN 9, 5009 BERGEN
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

BerGenBio is a clinical-stage biopharmaceutical company that develops innovative drugs for aggressive diseases. The company's primary focus is on its pipeline of first-in-class selective AXL kinase inhibitors, with its lead candidate being bemcentinib. These inhibitors are designed to treat conditions such as cancer and severe respiratory infections by targeting AXL, a key mediator of drug resistance, immune evasion, and metastasis. In June 2025, the company announced a proposed merger with Oncoinvent, an innovator in radiopharmaceutical cancer therapies, to expand its oncology pipeline and therapeutic capabilities.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-17 08:56
Share Issue/Capital Change
BerGenBio ASA: Updated Key Information related to the contemplated Rights Issue
English 10.0 KB
2025-09-17 08:55
Share Issue/Capital Change
BerGenBio ASA: Updated information regarding the contemplated Rights Issue and …
English 3.6 KB
2025-08-20 07:00
Interim Report
BerGenBio First half results 2025 - Attachment: H1_2025_Financial_report.pdf
English 905.6 KB
2025-08-20 07:00
Earnings Release
BerGenBio First half results 2025
English 5.4 KB
2025-08-05 16:49
Share Issue/Capital Change
BerGenBio ASA - Updated key information related to the rights issue
English 10.0 KB
2025-08-04 13:40
Post-Annual General Meeting Information
BerGenBio ASA: Approval of the merger plan and the fully underwritten rights is…
Norwegian 794.1 KB
2025-08-04 13:40
M&A Activity
BerGenBio ASA: Approval of the merger plan and the fully underwritten rights is…
English 2.2 KB
2025-07-03 14:53
Pre-Annual General Meeting Information
BerGenBio ASA: Notice of Extraordinary General Meeting - Attachment: BerGenBio_…
Norwegian 441.1 KB
2025-07-03 14:53
Pre-Annual General Meeting Information
BerGenBio ASA: Notice of Extraordinary General Meeting
English 2.6 KB
2025-06-30 22:30
Share Issue/Capital Change
BerGenBio ASA - Key information related to the rights issue
English 10.0 KB
2025-06-30 22:05
Share Issue/Capital Change
Announcement of fully underwritten rights issue - Attachment: Attachment_overvi…
English 101.2 KB
2025-06-30 22:05
Share Issue/Capital Change
Announcement of fully underwritten rights issue
English 21.0 KB
2025-06-30 22:00
M&A Activity
BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer ther…
English 19.5 KB
2025-06-26 11:29
Post-Annual General Meeting Information
BerGenBio ASA - Minutes from the annual general meeting 2025 - Attachment: BerG…
Norwegian 419.9 KB
2025-06-26 11:29
Post-Annual General Meeting Information
BerGenBio ASA - Minutes from the annual general meeting 2025
English 1.1 KB

Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for BerGenBio via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain IKM
AI-powered genome sequencing and reanalysis to diagnose rare diseases globally.
South Korea 394800
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea 174900
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea 203400
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea 298380
Acticor Biotech Logo
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
France ALACT
Adecco Group AG Logo
Global talent solutions firm offering staffing, placement, career transition, and tech consulting.
Switzerland ADI1
ADforus Co., Ltd. Logo
Ad-tech firm with AI platforms for mobile marketing and publisher monetization solutions.
South Korea 397810
Adocia Logo
Biotech improving protein drug formulations for diabetes & obesity and developing cell therapies.
France ADOC
ad pepper media International N.V. Logo
Global performance marketing & audience targeting solutions for advertisers and agencies worldwide.
Germany APM

Talk to a Data Expert

Have a question? We'll get back to you promptly.